Dapagliflozin with MetforminGLIFIROZ M 10/500 TABLET

Glifiroz M is a powerful fixed-dose combination of Dapagliflozin and Metformin (ER), designed for effective glycemic control in type 2 diabetes mellitus (T2DM). Dapagliflozin promotes urinary glucose excretion, aiding in blood sugar reduction, weight loss, and offering cardiorenal protection. Metformin (ER) reduces hepatic glucose production and enhances insulin sensitivity, with extended release ensuring GI tolerance and better patient adherence. This dual-mechanism approach provides comprehensive metabolic, cardiovascular, and renal benefits, making Glifiroz M ideal for first-line or add-on therapy in T2DM.

• Dosage:Once Daily with food OR as directed by the Physician
• Form: Tablet
• Indications:
  1. Diabetic Nephropathy
  2. Diabetes Mellitus type 2
• Composition: Dapagliflozin 10 mg Metformin (as extended release) 500 mg.
• Mode of Action:Glifiroz M combines Dapagliflozin, a selective sodium-glucose cotransporter type 2 (SGLT2) inhibitor, and Metformin, delivering synergistic control in type 2 diabetes mellitus. Dapagliflozin blocks glucose reabsorption in the renal proximal tubules, promoting urinary glucose excretion, aiding weight loss, and lowering systolic blood pressure by reducing sodium reabsorption—benefiting both glycemic and cardiovascular parameters. Metformin complements this by suppressing hepatic glucose output, reducing intestinal glucose absorption, and enhancing insulin sensitivity via AMP-activated protein kinase (AMPK) activation. This dual-action therapy ensures comprehensive gluco-metabolic and cardiorenal protection. Ideal for overweight patients, those with early diabetic nephropathy, uncontrolled HbA1c (glycated hemoglobin) on monotherapy, or at risk of cardiovascular events, Glifiroz M offers a dual mechanism for comprehensive T2DM management.
• Packaging:10*10’S
• Therapy Area: Anti Diabetic Renal medicine